Back to results
US 7,465,446 B2Granted
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
AssigneeMedarex, Inc.
InventorsIsrael Lowy, Geoffrey M. Nichol
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
Claims19
A method for treating cancer in a patient in need of such treatment, which method comprises administering an anti-CTLA-4 antibody in a dosage sufficient to induce a breakthrough event and detecting the breakthrough event.
A method for treating melanoma in a patient in need of such treatment, which method comprises administering anti-CTLA-4 antibody 10D1 in a dosage sufficient to induce a breakthrough event and detecting the breakthrough event.
Dependencies are inferred from the claim text.